What Is an Antinuclear Antibody (ANA) Blood Test?

ANA stands for antinuclear antibodies, a group of immune proteins that mistakenly target components inside your own cell nuclei. In routine medicine, “ANA” almost always refers to the blood test used to detect these antibodies, typically ordered when a doctor suspects an autoimmune condition such as lupus, Sjögren’s syndrome, or scleroderma. A positive result does not automatically mean you have an autoimmune disease, though, because a sizable fraction of healthy people carry detectable antinuclear antibodies without ever developing symptoms.

How Antinuclear Antibodies Form

Your immune system constantly generates new antibodies through a semi-random genetic reshuffling process. Occasionally that process produces antibodies directed against your own tissues. Normally, built-in checkpoints catch these self-targeting cells early and shut them down or destroy them. When those checkpoints fail, self-reactive immune cells survive and begin producing antibodies against nuclear material like DNA, histones, and other proteins found inside the nucleus of every cell.

Research into why the checkpoints fail points to several converging problems. Defects in the molecular machinery that normally forces self-reactive immune cells to self-destruct allow those cells to persist. Once they do, nuclear material from dying cells can further stimulate the immune system, especially through pathways involving nucleic-acid-sensing receptors on immune cells. These combined failures tend to produce antibodies directed at nuclear components rather than, say, muscle or liver proteins, likely because the immune system has so many natural pathways primed to respond to nucleic acids.¹

What the ANA Test Actually Measures

When your doctor orders an ANA test, the lab is looking for antibodies in your blood that bind to cell nuclei. The original and still widely used method is called indirect immunofluorescence, or IIF. In this technique, your diluted blood serum is placed on a slide coated with a specific line of human cells. If antinuclear antibodies are present, they latch onto the nuclei. A fluorescent dye then lights them up under a microscope, producing a visible pattern that the lab technician reads and reports.

The alternative is an enzyme-linked immunosorbent assay, usually called ELISA, which automates the process and delivers a numerical readout rather than relying on someone interpreting a fluorescent image. Comparisons between the two methods have produced mixed results. One study found that ELISA picked up a higher percentage of confirmed connective tissue disease cases than IIF, with better sensitivity for lupus and Sjögren’s syndrome.² Another study found the two methods had equal sensitivity for lupus, but IIF had lower specificity, meaning it flagged more people who did not actually have the disease.³ A third comparison found that IIF was better at ruling lupus out when the test came back negative, while ELISA was better at avoiding false positives.⁴

In practice, many labs still use IIF as the initial screen because it remains broadly accepted as the traditional standard. But the choice of method matters, especially at borderline titer levels, and results from one method are not always directly comparable to the other.

Understanding ANA Titers

An ANA result is usually reported as a titer, which reflects how much your blood serum can be diluted before the antibodies are no longer detectable. A titer of 1:80 means the antibodies were still visible after diluting your serum 80-fold. A titer of 1:320 means they were detectable at a much greater dilution, indicating a higher concentration of antibodies. Higher titers are generally more clinically meaningful, though no single cutoff cleanly separates “sick” from “healthy.”

A study evaluating how well different dilutions distinguish healthy people from those with confirmed connective tissue diseases found that about a fifth of healthy individuals tested positive at the 1:40 dilution, while roughly one in ten were positive at 1:80. By 1:320 the false-positive rate in healthy controls dropped to under 1%. The same study found that the 1:80 dilution offered the best balance between catching real disease and avoiding false alarms.⁵ Most labs now use 1:80 or 1:160 as their reporting threshold, which means a result reported as “positive” already accounts for the fact that very low-level antibodies are common and usually insignificant.

What the Staining Patterns Mean

When the IIF method is used, the lab does not just report whether the test is positive. The technician also describes the pattern in which the fluorescence lights up the nucleus. These patterns give doctors clues about which specific nuclear targets the antibodies are attacking, and by extension, which diseases to suspect.

The most common patterns include homogeneous (the entire nucleus glows evenly), speckled (scattered dots across the nucleus), nucleolar (bright staining confined to the nucleoli), and centromere (discrete dots in dividing cells). A homogeneous pattern often points toward lupus or drug-induced lupus, because it tends to reflect antibodies against DNA or histones. Speckled patterns are more diverse and can show up in Sjögren’s syndrome, mixed connective tissue disease, and other conditions. Centromere patterns are strongly associated with a subtype of scleroderma called limited cutaneous systemic sclerosis.

One large study examined whether ANA patterns were linked to cancer risk and found that a combined homogeneous-and-speckled pattern was associated with a lower risk of malignancy, while a nucleolar pattern carried an increased risk.⁶ That finding is intriguing but preliminary, and ANA patterns are not used clinically to screen for cancer.

Positive ANA in Healthy People

One of the most common sources of anxiety around ANA testing is that plenty of people without any autoimmune disease test positive. A well-known study of healthy individuals found that roughly a third were ANA-positive at a 1:40 dilution, about 13% at 1:80, 5% at 1:160, and 3% at 1:320.⁷ Those are substantial numbers, and they mean a positive ANA on its own, without symptoms pointing toward a specific disease, is a weak predictor of anything.

Women are more likely to test positive than men, a pattern that holds in both healthy people and those with autoimmune conditions.⁸ Whether prevalence increases with age is debated. Some reviews report higher rates in the elderly, while at least one analysis found age was not a significant predictor of ANA levels after accounting for other factors.⁹ The practical takeaway is that a low-titer positive ANA without joint pain, skin rashes, unexplained fevers, or other clinical signs is usually not a reason for alarm.

Which Diseases Are Associated with ANA

ANA testing is most closely tied to connective tissue diseases, a family of autoimmune conditions in which the immune system attacks the structural framework of the body. In a large cohort of patients who were ANA tested and eventually received a confirmed diagnosis, lupus was by far the most common condition, making up about 72% of cases. Sjögren’s syndrome accounted for about 13%, scleroderma roughly 8%, and inflammatory myositis and mixed connective tissue disease made up most of the rest.¹⁰

After a positive ANA, doctors typically order more specific antibody tests to narrow down the diagnosis. These include:

Anti-dsDNA: antibodies against double-stranded DNA, strongly associated with lupus and assigned the highest weighting in modern lupus classification criteria.¹¹
Anti-Smith (anti-Sm): highly specific for lupus, though not everyone with lupus has them.
Anti-SSA/Ro and anti-SSB/La: linked to Sjögren’s syndrome and some forms of lupus.
Anti-Scl-70: associated with the diffuse form of scleroderma.
Anti-Jo-1: linked to inflammatory myositis, especially polymyositis.
Anti-RNP: the hallmark of mixed connective tissue disease, though it turns up in other conditions too.¹²

These follow-up tests are sometimes grouped under the term “extractable nuclear antigen” or ENA panel. One study of over 500 patients found that half had at least one positive ENA antibody, and that moderate-to-high ANA titers of 1:320 or above were strongly associated with ENA positivity. Interestingly, about 9% of patients who tested negative on the initial ANA screen still turned out to be ENA-positive, a reminder that no single test captures everything.¹³

When Medications Trigger ANA

Certain drugs can provoke the body into producing antinuclear antibodies, sometimes even triggering a lupus-like syndrome called drug-induced lupus. Classic offenders include procainamide (a heart rhythm medication) and hydralazine (a blood pressure drug).¹⁴ In more recent years, biologic medications that block tumor necrosis factor alpha, used for conditions like rheumatoid arthritis and Crohn’s disease, have become an increasingly recognized trigger.¹⁵

Drug-induced lupus usually looks milder than the spontaneous kind. One distinguishing feature is the presence of anti-histone antibodies, often at very high levels, alongside a positive ANA with a homogeneous pattern. A case report described a patient on statins who developed drug-induced lupus with ANA titers of 1:1,280 and anti-histone antibody levels above 200 U/mL, while anti-dsDNA antibodies remained low.¹⁶ The good news is that drug-induced lupus generally resolves once the offending medication is stopped, though the antibodies themselves can linger in the bloodstream for months afterward.

The Problem with Repeat Testing

If you tested positive for ANA once, you might assume your doctor would want to recheck it periodically. In practice, repeating the test is rarely useful. A study examining repeated ANA tests found that about two-thirds of results stayed the same when the test was rerun. Results at moderate and high titers essentially never changed. The seroconversions that did occur were almost exclusively at the borderline range, shifting between negative and weakly positive.¹⁷

A larger study tracked over 2,600 patients with an initially negative ANA. About 19% eventually had a positive result on a repeat test, but when researchers checked whether that conversion led to an actual new diagnosis, only about 1% of those patients received a diagnosis of an ANA-associated rheumatic disease. The researchers concluded that repeating ANA tests after a negative result has low clinical utility and drives up costs without improving patient care.¹⁸ This is one of those areas where both doctors and patients tend to reach for more testing, but the data consistently says less is more.

ANA Testing Is Often Ordered When It Shouldn’t Be

A related problem is that ANA tests get ordered far too liberally. Because the test sounds definitive and autoimmune diseases can be scary, doctors sometimes order ANA screens for vague complaints like fatigue or generalized aches even when the clinical picture does not suggest an autoimmune condition. A retrospective study at a community hospital found that doctors frequently bypassed proper diagnostic sequencing, jumping to specific antibody panels before establishing a clinical reason to suspect autoimmune disease.¹⁹

This matters because a positive ANA in someone who was unlikely to have an autoimmune disease in the first place can set off a cascade of unnecessary follow-up tests, specialist referrals, and anxiety. Given that roughly one in eight healthy people will test positive at common screening dilutions, ordering the test without a reasonable pre-test suspicion virtually guarantees a pile of false positives.²⁰ The test works best when it is used to confirm a suspicion that already existed on clinical grounds, not as a fishing expedition.

ANA in Children

ANA testing comes up in pediatrics most often in the context of juvenile idiopathic arthritis, the most common form of childhood arthritis. In that setting, the antibodies themselves are less about diagnosing the arthritis and more about predicting a dangerous complication: uveitis, an inflammatory eye condition that can permanently damage vision if not caught early. Children with juvenile idiopathic arthritis who test ANA-positive are more likely to develop uveitis than those who test negative.²¹

A meta-analysis looking at how well ANA predicts uveitis in these children found the test had moderate sensitivity and specificity at the commonly used 1:40 dilution, meaning it catches most at-risk children but also flags some who will never develop eye problems.²² Because of this, ANA-positive children with juvenile idiopathic arthritis are typically referred for more frequent ophthalmologic screening than their ANA-negative peers.

Environmental Exposures and ANA

Beyond genetics and immune dysfunction, environmental exposures can nudge the immune system toward producing antinuclear antibodies. Tobacco exposure stands out in the research. Among patients with interstitial lung disease, those with a history of tobacco use were more likely to be ANA-positive than those without, an association that held up after adjusting for other factors. Inorganic dust exposures showed a similar independent association.²³

Silica exposure has long been suspected as a trigger for autoimmune responses. In scleroderma specifically, a study of over 600 patients found that those with prior environmental exposures including silica, organic solvents, and pesticides had distinct clinical profiles, and interestingly, those with diffuse scleroderma and environmental exposures actually had lower rates of ANA positivity than unexposed patients.²⁴ That finding runs somewhat counter to the general expectation, and it suggests the relationship between environmental triggers and autoimmunity is not as straightforward as “exposure equals more antibodies.”

ANA in Dogs and Cats

Autoimmune diseases are not unique to humans, and neither are antinuclear antibodies. Veterinarians test for ANA in dogs and cats using techniques adapted from human laboratories. In dogs, a homogeneous ANA staining pattern tends to correlate with anti-dsDNA and anti-nucleosome antibodies, while a speckled pattern is more associated with anti-RNP and anti-Smith antibodies, a distribution that loosely mirrors the patterns seen in people.²⁵

Cats present their own diagnostic wrinkle. A study of healthy client-owned cats found that 30% tested positive for ANA, with 20% showing titers of 1:160 or higher. By contrast, facility-housed cats had far lower rates of positivity, with 96% testing negative. The gap likely reflects differences in environmental exposure, stress, and infectious disease history.²⁶ Just as in humans, a positive ANA in a seemingly healthy animal does not equal disease, and veterinarians face the same interpretive challenges that physicians do.

1
PubMed Central. B-cell tolerance and autoimmunity ↩︎
2
PubMed Central. Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases ↩︎
3
PubMed Central. Comparison of Indirect Immunofluorescence and Enzyme Immunoassay for the Detection of Antinuclear Antibodies ↩︎
4
Annals of the Rheumatic Diseases. Comparison of Indirect Immunofluorescence (IIF) on HEP-2 Cells, Enzyme-Linked Immunosorbent Assay (ELISA) and Multiplex Bead-Based Immunoassay for Detection of Antinuclear Antibodies (ANA) in Systemic Lupus Erythematosus (SLE) ↩︎
5
PubMed Central. Assessment of ideal serum dilution for screening of antinuclear antibodies by an indirect immunofluorescence method in diagnosis of autoimmune disorders ↩︎
6
PubMed Central. Antinuclear Antibodies With a Homogeneous and Speckled Immunofluorescence Pattern Are Associated With Lack of Cancer While Those With a Nucleolar Pattern With the Presence of Cancer ↩︎
7
PubMed. Range of antinuclear antibodies in “healthy” individuals ↩︎
8
PubMed Central. Risk factors for ANA positivity in healthy persons ↩︎
9
PubMed Central. Antinuclear antibodies in healthy people and non-rheumatic diseases – diagnostic and clinical implications ↩︎
10
Scientific Reports. Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases ↩︎
11
PubMed Central. Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus ↩︎
12
National Journal of Laboratory Medicine. An Overview of Various Diagnostic Methods to Detect Antinuclear Antibodies of Connective Tissue Diseases ↩︎
13
Cureus. Assessment of the Impact of Anti-nuclear Antibody (ANA) Titer and Pattern on Anti-extractable Nuclear Antigen (ENA) Positivity: Experience at Cheikh Khalifa Hospital ↩︎
14
PubMed. Drug-induced lupus: Traditional and new concepts ↩︎
15
PubMed. Drug-induced lupus: an update ↩︎
16
PubMed Central. A Severe Presentation of Drug-Induced Lupus Erythematosus ↩︎
17
PubMed Central. Frequency of Repeating Antinuclear Antibody Testing: When Less Is More ↩︎
18
The Lancet Rheumatology. Utility and frequency of repeat antinuclear antibody testing ↩︎
19
PubMed Central. Inappropriate use of commercial Antinuclear Antibody Testing in a community-based US hospital: a retrospective study ↩︎
20
ACR Meeting Abstracts. Improper Use of Antinuclear Antibody (ANA) Test Can Result in Misdiagnosis, Increased Patient Anxiety, and Wasted Health Care Resources ↩︎
21
PubMed Central. Uveitis Associated with Juvenile Idiopathic Arthritis, our Observations ↩︎
22
PubMed. Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis ↩︎
23
ERJ Open Research. Association of antinuclear antibody seropositivity with inhaled environmental exposures in patients with interstitial lung disease ↩︎
24
PubMed. Is exposure to environmental factors associated with a characteristic clinical and laboratory profile in systemic sclerosis? ↩︎
25
PubMed. Identification of specific antinuclear antibodies in dogs using a line immunoassay and enzyme-linked immunosorbent assay ↩︎
26
PubMed. Prevalence of antinuclear and anti-erythrocyte antibodies in healthy cats ↩︎